{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"

PRODIGE\n107- ENGIC 01- COLOSOTO

\n\n

A single-arm phase II\nstudy evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib\n(KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a\ndoublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated\ncolorectal adenocarcinoma

","eudractNumber":"2024-514030-20-00","id":11576,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2026-02-04T14:05:28+01:00","shortTitle":"PRODIGE 107-COLOSOTO","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
Pre-Operative Treatment in rEseCTable cOlon canceR
(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)
Prospective, randomized, open, multicenter Phase III trial
to investigate the efficacy preoperative systemic therapy in
advanced colon cancer
","eudractNumber":"2023-508076-11-00","id":11330,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-01T08:30:33+02:00","shortTitle":"PROTECTOR/ Fire-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
Pädiatrisches Register für Stammzelltransplantationen und ZellTherapie (PRSZT)
","eudractNumber":null,"id":965,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2013-09-18T09:10:24+02:00","shortTitle":"PRSZT (ehemals PRST)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positivem Mammakarzinom / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":7720,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-12T14:28:59+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positiven MammaCa / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
","eudractNumber":null,"id":10616,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"}],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-03-13T08:39:41+01:00","shortTitle":"PaTyp","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

Prophylaktische\nWirkung eines retromuskulären Netzes während Ileostomarückverlagerung auf die\nInzidenz von Narbenhernien – eine multizentrische randomisierte Patienten- und\nBeobachter-verblindete Studie

\n\n(P.E.L.I.O.N.\nTrial)
DRKS00027921
","eudractNumber":null,"id":9368,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-03-04T12:15:13+01:00","shortTitle":"Pelion","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Phase\nII trial of Pembrolizumab in COmbination with salvage\nchemotherapy for first-RElapsed or refractory classical Hodgkin lymphoma","eudractNumber":"2022-501306-35","id":8371,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT04838652","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-12-04T14:43:15+01:00","shortTitle":"Pembro-CORE pilot","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"

Etablierung kontinuierlicher perioperativer\nBlutglucosemessungen zur Detektion metabolischer Veränderungen bei Patienten in\nder Viszeralchirurgie: Machbarkeits- und Etablierungsstudie

","eudractNumber":null,"id":11032,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-06-15T13:14:09+02:00","shortTitle":"PeriOPGlukose","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Anwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)

NIS-Nr.:742
","eudractNumber":null,"id":9261,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-02-15T13:25:54+01:00","shortTitle":"Privigen","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
","eudractNumber":null,"id":9044,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-09-16T11:10:02+02:00","shortTitle":"ProspectPass/ Cartitude P9","therapeutical":false,"therapyLines":[]}]},"initialUrl":"/api/studies?lang=de&page=27&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

PRODIGE\\n107- ENGIC 01- COLOSOTO

\\n\\n

A single-arm phase II\\nstudy evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib\\n(KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a\\ndoublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated\\ncolorectal adenocarcinoma

\",\"name\":\"PRODIGE 107-COLOSOTO\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11576\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
Pre-Operative Treatment in rEseCTable cOlon canceR
(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)
Prospective, randomized, open, multicenter Phase III trial
to investigate the efficacy preoperative systemic therapy in
advanced colon cancer
\",\"name\":\"PROTECTOR/ Fire-10\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11330\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
Pädiatrisches Register für Stammzelltransplantationen und ZellTherapie (PRSZT)
\",\"name\":\"PRSZT (ehemals PRST)\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/965\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positivem Mammakarzinom / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
\",\"name\":\"PaTyp\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7720\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Patienten-Typologisierung für ein bedarfsgerechtes und effektiveres Coaching bei Patientinnen mit Hormonrezeptor positiven MammaCa / PaTyp

VERSORGUNGSFORSCHUNGSSTUDIE
\",\"name\":\"PaTyp\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10616\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

Prophylaktische\\nWirkung eines retromuskulären Netzes während Ileostomarückverlagerung auf die\\nInzidenz von Narbenhernien – eine multizentrische randomisierte Patienten- und\\nBeobachter-verblindete Studie

\\n\\n(P.E.L.I.O.N.\\nTrial)
DRKS00027921
\",\"name\":\"Pelion\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9368\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Phase\\nII trial of Pembrolizumab in COmbination with salvage\\nchemotherapy for first-RElapsed or refractory classical Hodgkin lymphoma\",\"name\":\"Pembro-CORE pilot\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8371\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

Etablierung kontinuierlicher perioperativer\\nBlutglucosemessungen zur Detektion metabolischer Veränderungen bei Patienten in\\nder Viszeralchirurgie: Machbarkeits- und Etablierungsstudie

\",\"name\":\"PeriOPGlukose\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11032\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Anwendung von Privigen® bei sekundärer Immunschwäche: Eine multizentrische Beobachtungsstudie (IgPro10_5008)

NIS-Nr.:742
\",\"name\":\"Privigen\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9261\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Post-authorization Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel
\",\"name\":\"ProspectPass/ Cartitude P9\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9044\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=28\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}